These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39187175)

  • 1. Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice.
    Aguilera García I; García Moreno RM; López Plaza B; Barquiel Alcalá B; Vázquez Pérez P; Barreda Bonis AC; Zamarrón de Lucas E; Palma Milla S; Prados Sánchez MC; González Pérez de Villar N
    Diabetes Res Clin Pract; 2024 Oct; 216():111839. PubMed ID: 39187175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.
    Castaldo A; Iacotucci P; Bagnasco S; Fevola C; Carnovale V; Antonelli F; Cernera G; Gelzo M; Terlizzi V
    Sci Rep; 2024 Jul; 14(1):17422. PubMed ID: 39075279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Obesity a Problem in New Cystic Fibrosis Treatments?
    Solís-García M; García-Clemente MM; Madrid-Carbajal CJ; Peláez A; Gómez Punter RM; Eiros Bachiller JM; Girón Moreno RM
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants.
    Pinto MO; Santos AS; Castanhinha S
    Pulmonology; 2024; 30(5):485-487. PubMed ID: 38614858
    [No Abstract]   [Full Text] [Related]  

  • 8. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 12. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.
    Park J; Walsh A; Kerr S; Woodland C; Southward S; Deakin M; Senniappan S; Thursfield R
    Horm Res Paediatr; 2024; 97(1):94-98. PubMed ID: 37040724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
    Gonçalves Martynychen Canan M; Souza Sokoloski C; Rossetti Severo C; Zahi Rached S; Abensur Athanazio R
    Arch Bronconeumol; 2024 Aug; 60(8):526-528. PubMed ID: 38714384
    [No Abstract]   [Full Text] [Related]  

  • 16. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.
    Loske J; Völler M; Lukassen S; Stahl M; Thürmann L; Seegebarth A; Röhmel J; Wisniewski S; Messingschlager M; Lorenz S; Klages S; Eils R; Lehmann I; Mall MA; Graeber SY; Trump S
    Am J Respir Crit Care Med; 2024 Jun; 209(11):1338-1350. PubMed ID: 38259174
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two
    Stahl M; Dohna M; Graeber SY; Sommerburg O; Renz DM; Pallenberg ST; Voskrebenzev A; Schütz K; Hansen G; Doellinger F; Steinke E; Thee S; Röhmel J; Barth S; Rückes-Nilges C; Berges J; Hämmerling S; Wielpütz MO; Naehrlich L; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 38901883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Middleton PG; Simmonds NJ
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 39326905
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.